Neurocrine initiated with neutral view at Citi, here’s why

Citi analyst David Hoang initiated coverage of Neurocrine Biosciences with a Neutral rating and $127 price target. With a market cap near $12B, Neurocrine shares are fairly valued on the commercial prospects for Ingrezza in Huntington’s disease-associated chorea and tardive dyskinesia as well as crinecerfont in congenital adrenal hyperplasia, the analyst tells investors in a research note. The firm is less bullish than the Street, modeling peak sales of $2.5B versus the $3.0B consensus. Citi remains on the sidelines until Neurocrine’s pipeline “can materialize a compelling asset that rivals Ingrezza’s potential.”